FDA Is Expanding Transparency Efforts To Focus On Industry Questions
This article was originally published in The Gray Sheet
Executive Summary
FDA has expanded its transparency initiative to cover an area that was unanticipated, Deputy Director Joshua Sharfstein said: explaining how the agency works to the industry it regulates